WallStreetZenWallStreetZen

NASDAQ: NUVL
Nuvalent Inc Stock

Overview
ForecastEarningsRevenueDividendOwnership
$99.32+1.15 (+1.17%)
Updated Oct 31, 2025
NUVL Price
$99.32
Fair Value Price
$2.19
Market Cap
$7.22B
52 Week Low
$55.54
52 Week High
$104.90
P/E
-18.63x
P/B
8.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$381.44M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.16
Operating Cash Flow
-$264M
Beta
1.51
Next Earnings
Nov 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A

NUVL Overview

Nuvalent, Inc. is developing cancer therapies meant to overcome the limitations of existing therapies for clinically proven kinase targets. Its lead product candidate, NVL-520, is a brain-penetrant ROS1-selective inhibitor. Nuvalent was incorporated in 2017 and is headquartered in Cambridge, MA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine NUVL's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

C
Value
D
Growth
C
Momentum
D
Sentiment
C
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
NUVL
Ranked#355 of 488

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Mimedx Group (MDXG)
$7.65A
Incyte (INCY)
$93.48A
Theravance Biopharma (TBPH)
$14.66A
View Top Biotech Stocks

Be the first to know about important NUVL news, forecast changes, insider trades & much more!

NUVL News

Overview

Due Diligence Score

–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NUVL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NUVL ($99.32) is overvalued by 4,427.21% relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NUVL ($99.32) is not significantly undervalued (4,427.21%) relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NUVL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NUVL due diligence checks available for Premium users.

Valuation

NUVL fair value

Fair Value of NUVL stock based on Discounted Cash Flow (DCF)

Price
$99.32
Fair Value
$2.19
Overvalued by
4,427.21%
NUVL ($99.32) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NUVL ($99.32) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NUVL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NUVL price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-18.63x
Industry
-9.17x
Market
41.65x

NUVL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
8.54x
Industry
4.99x
NUVL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NUVL's financial health

Profit margin

Revenue
$0.0
Net Income
-$122.4M
Profit Margin
0%
NUVL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$979.9M
Liabilities
$134.5M
Debt to equity
0.16
NUVL's short-term assets ($956.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NUVL's short-term assets ($956.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NUVL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$70.5M
Investing
$54.0M
Financing
$4.8M
NUVL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NUVL vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
NUVLD$7.22B+1.17%-18.63x8.54x
MRUS–$7.17B-0.21%-17.25x8.52x
RYTMC$7.56B+1.74%-37.79x-634.53x
CYTKC$7.59B+2.15%-12.02x-28.51x
HALOA$7.63B+0.87%14.55x22.92x
View Top Biotech Stocks

Nuvalent Stock FAQ

What is Nuvalent's quote symbol?

(NASDAQ: NUVL) Nuvalent trades on the NASDAQ under the ticker symbol NUVL. Nuvalent stock quotes can also be displayed as NASDAQ: NUVL.

If you're new to stock investing, here's how to buy Nuvalent stock.

What is the 52 week high and low for Nuvalent (NASDAQ: NUVL)?

(NASDAQ: NUVL) Nuvalent's 52-week high was $104.90, and its 52-week low was $55.54. It is currently -5.32% from its 52-week high and 78.84% from its 52-week low.

How much is Nuvalent stock worth today?

(NASDAQ: NUVL) Nuvalent currently has 72,706,715 outstanding shares. With Nuvalent stock trading at $99.32 per share, the total value of Nuvalent stock (market capitalization) is $7.22B.

Nuvalent stock was originally listed at a price of $18.75 in Jul 29, 2021. If you had invested in Nuvalent stock at $18.75, your return over the last 4 years would have been 429.71%, for an annualized return of 51.71% (not including any dividends or dividend reinvestments).

How much is Nuvalent's stock price per share?

(NASDAQ: NUVL) Nuvalent stock price per share is $99.32 today (as of Oct 31, 2025).

What is Nuvalent's Market Cap?

(NASDAQ: NUVL) Nuvalent's market cap is $7.22B, as of Nov 2, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Nuvalent's market cap is calculated by multiplying NUVL's current stock price of $99.32 by NUVL's total outstanding shares of 72,706,715.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.